Phase 1 N=603 Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer
Breast Cancer
Primary: Percentage of Participants With Reoccurrence — 90.7; 87.5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=61 Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058)
Non-Small Cell Lung Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLT) Due to Vorinostat Administered in Combination With Standard Dose of Gemcitabine Plus Either Cisplatin or…
Phase 1 N=115 Pharmacokinetics and Safety Study of Tipranavir in Combination With Low Dose Ritonavir in Human Immunodeficiency Virus (HIV)-Infected Children
HIV Infections
Primary: Number of Severe (DAIDS Grades 3 or 4) Adverse Events Related to Drug for Treated Patients by Age Group and Formulation — 2; 6; 3; 2 participants
Phase 1 N=42 Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
Hemophilia A
Primary: Area Under the Curve — 1257.20; 1297.42 IU*h/dL
Phase 1 N=18 Bioavailability Study Comparing 10 Mg Amlodipine Besylate Orally Disintegrating Tablet (ODT) And 10 Mg Amlodipine Besylate Tablets
Healthy Volunteers
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 307.225; 324.324; 330.411 hr*ng/mL
Phase 1 N=25 Pharmacokinetic Study of ARALAST (Human Alpha1- PI)
Alpha 1-Antitrypsin Deficiency
Primary: Area Under the Curve/Dose — 0.0822; 0.0920 days*kg/mL
Phase 1 N=29 Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Metastatic Solid Tumor
Primary: Maximum Tolerated Dosage (MTD) of Intravenous Topotecan When Given in Combination With Oral Erlotinib — 1.0 mg/m^2
Phase 1 N=49 Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease
Alzheimer's Disease · Central Nervous System Diseases
Primary: Safety and Tolerability of Multiple Doses of EVP-6124 or Placebo in Subjects With Alzheimer's Disease — 0; 0; 0; 0 Participants
Phase 1 N=61 An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Area Under the Plasma Concentration-time Curve (AUC) 0-72 Hours — 123; 170; 215 ng*h/mL
Phase 1 N=16 Eletriptan Pharmacokinetics In Korean Males
Healthy
Primary: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] — 291.3; 575.6; 1282.0; 1278.0 ng* hr/mL
Phase 1 N=448 Sugammadex Hypersensitivity Study (Study P06042)
Hypersensitivity
Primary: The Percentage of Participants With Adjudicated Hypersensitivity Signs/Symptoms, for Each Sugammadex Dose Group and Placebo. — 0.7; 4.7; 0 percentage of participants
Phase 1 N=17 MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
Hepatitis C
Primary: Number of Participants With Vaccine-related Clinical (Systemic and Injection-site), and Laboratory Adverse Events (AE) — 5; 1; 3; 1 Participants
Phase 1 N=317 A Study of Safety, Tolerability, and Immunogenicity of the MRKAd5 Gag/Pol/Nef Vaccine in Healthy Adults (V520-016)
HIV-1 · HIV Infections
Primary: Number of Participants With Adverse Experiences — 20; 13; 36; 33 Participants
Phase 1 N=20 Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Phase 1 N=43 Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects
Attention Deficit Hyperactivity Disorder
Primary: Safety and Tolerability — 2 events